Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 12/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064806 | 0.92 | SIGMAR1 (0.40) | SIGMAR1GNAO1GNAI3GNAI1 | |
| SCHEMBL27666610 | 0.90 | SIGMAR1 (0.46) | SIGMAR1GNAO1GNAI3GNAI1HRH4 | |
| SCHEMBL4723821 | 0.85 | SIGMAR1 (0.44) | SIGMAR1GNAO1GNAI3GNAI1HRH4 | |
| SCHEMBL19040775 | 0.85 | GNAO1 (0.43) | SIGMAR1GNAO1GNAI3GNAI1DNM1 | |
| SCHEMBL4724864 | 0.80 | SIGMAR1 (0.42) | SIGMAR1GNAO1GNAI3GNAI1HRH4 | |
| SCHEMBL4722679 | 0.79 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL10444399 | 0.79 | DNM1 (0.39) | SIGMAR1GNAO1GNAI3GNAI1DNM1 | |
| Hydrochloric Acid SCHEMBL29616253 | 0.78 | SIGMAR1 (0.35) | SIGMAR1GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL6291773 | 0.78 | SIGMAR1 (0.42) | SIGMAR1GNAO1GNAI3GNAI1DNM1 | |
| Bromide SCHEMBL6291201 | 0.78 | SIGMAR1 (0.42) | SIGMAR1GNAO1GNAI3GNAI1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895558-B2 | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | GREEN CROSS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010038948-A2 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | GREEN CROSS CORPORATION (KR) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178091-A1 | ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS | NPY5R, TPH2, MC5R | SIGMAR1 1205/4885GNAO1 1385/4885GNAI3 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.